Original Article

You have full text access to this OnlineOpen article

High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate

  1. Eva Reinhold-Keller1,*,
  2. Claudia O. E. Fink1,
  3. Karen Herlyn1,
  4. Wolfgang L. Gross1,
  5. Kirsten de Groot2

Article first published online: 5 JUN 2002

DOI: 10.1002/art.10459

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 47, Issue 3, pages 326–332, 15 June 2002

Additional Information

How to Cite

Reinhold-Keller, E., Fink, C. O. E., Herlyn, K., Gross, W. L. and de Groot, K. (2002), High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis & Rheumatism, 47: 326–332. doi: 10.1002/art.10459

Author Information

  1. 1

    Medical University of Lübeck, Lübeck, Germany

  2. 2

    Medical School of Hannover, Hannover, Germany

*Medizinische Universität Lübeck, Abteilung Klinische Rheumatologie, Oskar-Alexander-Strasse 26, D-24572 Bad Bramstedt, Germany

Publication History

  1. Issue published online: 5 JUN 2002
  2. Article first published online: 5 JUN 2002
  3. Manuscript Accepted: 1 NOV 2001
  4. Manuscript Received: 3 OCT 2001

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (83K)

REFERENCES

  • 1
    Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488–98.
  • 2
    Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nölle B, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021–32.
    Direct Link:
  • 3
    Jayne DRW, Rasmussen N, for the European Community Systemic Vasculitis Clinical Trials Study Group. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997; 72: 737–47.
  • 4
    Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35: 1322–9.
  • 5
    Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998; 9: 842–52.
  • 6
    Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608–13.
    Direct Link:
  • 7
    De Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Gross WL. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis: methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39: 2052–61.
    Direct Link:
  • 8
    Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666–73.
    Direct Link:
  • 9
    Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43: 1836–40.
    Direct Link:
  • 10
    De Groot K, Mühler M, Reinhold-Keller E, Paulsen J, Gross WL. Induction of remission in Wegener's granulomatosis with low-dose methotrexate. J Rheumatol 1998; 25: 492–5.
  • 11
    Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101–7.
    Direct Link:
  • 12
    Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an International Consensus Conference. Arthritis Rheum 1994; 37: 187–92.
    Direct Link:
  • 13
    De Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001; 55: 31–8.
  • 14
    Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, et al. Diagnostic value of standardized assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 1998; 53: 743–53.
  • 15
    Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, et al. Relapses in patients with systemic vasculitis. Q J Med 1993; 86: 779–89.
  • 16
    Ortiz Z, Shea B, Suarez-Almor D, Moher D, Wells G, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate induced gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. J Rheumatol 1998; 25: 36–43.
  • 17
    Van Ede AE, Laan RFJM, Rood MJ, Huizinga TWJ, van de Laar MAFJ, van Denderen CJ, et al. Effect of folic and folinic acid supplementation on toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight-week, multicenter randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 1515–24.
    Direct Link:
  • 18
    Endresen GKM, Husby G. Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. Scand J Rheumatol 2001; 30: 129–34.
  • 19
    Shiroky JB. The use of folates concomitantly with low-dose pulse methotrexate. Rheum Dis Clinic North Am 1997; 23: 969–80.
  • 20
    Jayne D, Gaskin D, for EUVAS. Randomized trial of cyclophosphamide versus azathioprine during remission in ANCA-associated vasculitis (CYCAZAREM). J Am Soc Nephrol 1999; 10: 105A.
  • 21
    Reinhold-Keller E, de Groot K, Gross WL. Reply to cystitis, bladder cancer, and myelodysplasia in patients with Wegener's granulomatosis [letter]. Arthritis Rheum 2000; 43: 2854–5.
    Direct Link:
  • 22
    Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Pilot Study of the Safety and Efficacy of Leflunomid (LEF) in Patients with Wegener's Granulomatosis (WG) in Remission. Ann Rheum Dis 2001; 60 Suppl 1: 133.
View Full Article (HTML) Get PDF (83K)